Nasal Polyposis - Pipeline Review, H1 2017

March 2017 | 48 pages | ID: N1A91CD4A64EN
Global Markets Direct

Abstracts

Nasal Polyposis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasal Polyposis - Pipeline Review, H1 2017, provides an overview of the Nasal Polyposis (Ear Nose Throat Disorders) pipeline landscape.

Nasal polyps (NP) are non cancerous growths within the nose or sinuses. Symptoms include runny nose, snoring, itchiness, persistent stuffy, facial pain, loss of taste. Risk factors include asthma, cystic fibrosis, Churg-Strauss syndrome and allergic fungal sinusitis. Treatment includes corticosteroids, antihistamines to treat allergies and antibiotics to treat a chronic or recurring infection.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasal Polyposis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Nasal Polyposis (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasal Polyposis (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasal Polyposis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Phase II stages are 1, 1 and 3 respectively.

Nasal Polyposis (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Nasal Polyposis (Ear Nose Throat Disorders).
• The pipeline guide reviews pipeline therapeutics for Nasal Polyposis (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Nasal Polyposis (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Nasal Polyposis (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Nasal Polyposis (Ear Nose Throat Disorders)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Nasal Polyposis (Ear Nose Throat Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Nasal Polyposis (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Nasal Polyposis - Overview
Nasal Polyposis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Nasal Polyposis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nasal Polyposis - Companies Involved in Therapeutics Development
Allakos Inc
Cumberland Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
OptiNose US Inc
Regeneron Pharmaceuticals Inc
Nasal Polyposis - Drug Profiles
AK-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dupilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluticasone propionate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ifetroban sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nasal Polyposis - Dormant Projects
Nasal Polyposis - Product Development Milestones
Featured News & Press Releases
Feb 09, 2017: Michael F. Marino Joins OptiNose as Chief Legal Officer
Jan 31, 2017: OptiNose Announces FDA Acceptance for Filing of the New Drug Application for OPN-375
Jan 26, 2017: OptiNose Appoints Keith Goldan as Chief Financial Officer
Sep 29, 2016: Tom Gibbs Joins OptiNose as Chief Commercial Officer
Sep 08, 2016: Allakos Initiates Phase 2 Trial of AK001 in Patients with Nasal Polyposis
Feb 03, 2016: Nasal polyps can be treated with medicine dupilumab
Feb 02, 2016: Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association
Sep 24, 2015: OptiNose Announces Positive Results of Second Phase III Pivotal Trial for OPN-375
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Nasal Polyposis, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Nasal Polyposis - Pipeline by Allakos Inc, H1 2017
Nasal Polyposis - Pipeline by Cumberland Pharmaceuticals Inc, H1 2017
Nasal Polyposis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Nasal Polyposis - Pipeline by OptiNose US Inc, H1 2017
Nasal Polyposis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Nasal Polyposis - Dormant Projects, H1 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development for Nasal Polyposis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017